# Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Study · id `cardio:ct-nct05679024` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05679024](<https://clinicaltrials.gov/study/NCT05679024>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05679024

Browse, organ or system: Heart; Brain; Kidneys  
Browse, condition area: Stroke; Heart rhythm problems; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1400 participants.

## Technical summary

Registry record NCT05679024. Randomized; no masking; primary purpose treatment. Start 2023-02-17 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1400 participants (planned count; ClinicalTrials.gov record NCT05679024, source copy `cardio:ctgov-nct05679024-2024-10-04`, retrieved 2026-10-26)
- Started: 2023-02-17 (actual) (ClinicalTrials.gov record NCT05679024, source copy `cardio:ctgov-nct05679024-2024-10-04`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT05679024, source copy `cardio:ctgov-nct05679024-2024-10-04`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05679024, source copy `cardio:ctgov-nct05679024-2024-10-04`, retrieved 2026-10-26)
- Countries: Finland; Iceland; Norway; Sweden (ClinicalTrials.gov record NCT05679024, source copy `cardio:ctgov-nct05679024-2024-10-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05679024-2024-10-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
- Acronym: SACK
- Condition: Chronic Kidney Diseases
- Condition: Atrial Fibrillation
- Condition: Stroke
- Condition: Intracerebral Hemorrhage
- Condition: Major Bleed
- Condition: Cardiovascular Complication
- Condition: Death
- Condition: Kidney Transplant; Complications
- Condition: Thromboses, Venous
- Intervention (Drug): Apixaban 2.5 milligram Oral Tablet
- Lead sponsor: Region Stockholm
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Region Stockholm (`cardio:org-region-stockholm`)

## Provenance

Content hash: f639a9b2a56a5ff025f50fc936402d5122ea771961ed059153ef0dbfccec5daa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
